Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt(Institute of Cancer Research), James Carmichael(AstraZeneca (United Kingdom)), Michael Friedländer(Prince of Wales Hospital), Jeffrey N. Weitzel(Cancer Genetics (United States)), Mark Wickens(AstraZeneca (United Kingdom)), Mark E. Robson(Memorial Sloan Kettering Cancer Center), M. William Audeh(Sheba Medical Center), Susan M. Domchek(University City Science Center), Andrew Wardley(UK Research and Innovation), Helena Earl(University of Cambridge), Banu Arun(The University of Texas MD Anderson Cancer Center), Gillian Mitchell(Peter MacCallum Cancer Centre), Judy E. Garber(Dana-Farber Cancer Institute), Rita K. Schmutzler(The University of Melbourne), Niklas Loman(Lund University)
Cited by 1,636
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer
|New England Journal of Medicine|2021|1.6k